In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity.
The influence of the renin-angiotensin system (RAS) on the aortic wall mechanical properties under angiotensin I converting enzyme inhibition (enalaprilat, 0.3 mg/kg iv) or angiotensin II receptor (AT1) blockade (E-3174, 1 mg/kg iv) was examined in eight normotensive and eight renovascular hypertensive conscious dogs. Aortic diameter (D; sonomicrometry)-pressure (P; microtransducer) hysteresis loops during steady state and during rapid distal aortic occlusion allowed (after hysteresis elimination) calculation of the aortic wall viscosity index, the purely elastic P-D relationship, and derivation into compliance-pressure curves. At the early stage ofrenovascular hypertension when activation of RAS is more pronounced, aortic wall stiffness and wall viscosity were increased as compared with normotensive states. Blood pressure remained unchanged in normotensive animals and was reduced during hypertension after antihypertensive treatments. In hypertensive animals, enalaprilat and E-3174 decreased viscosity index and shifted the compliance-pressure curve upward with respect to pretreatment conditions. In normotensive dogs, whereas E-3174 did not change the compliance-pressure curve and viscosity index, enalaprilat increased compliance and reduced viscosity index. We concluded that in normotensive dogs converting enzyme inhibition modifies arterial viscoelastic parameters by angiotensin-independent mechanisms that contribute to the modulation of the buffering function of large arteries.
Barra
J G
JG
Basic Sciences Research Institute, The René Favaloro University Foundation, Buenos Aires, Argentina.
Levenson
J
J
Armentano
R L
RL
Cabrera Fischer
E I
EI
Pichel
R H
RH
Simon
A
A
D000803:Angiotensin I / Q000037:antagonists & inhibitors; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001011:Aorta / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004548:Elasticity; D015773:Enalaprilat / Q000494:pharmacology; D006978:Hypertension, Renovascular / Q000503:physiopathology; D007093:Imidazoles / Q000494:pharmacology; D019808:Losartan; D008297:Male; D012016:Reference Values; D013777:Tetrazoles / Q000494:pharmacology; D014783:Viscosity
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; D000803:Angiotensin I; C066026:losartan carboxylic acid; D015773:Enalaprilat; D019808:Losartan